Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07460284) titled 'A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants' on Feb. 27.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Guangdong Raynovent Biotech Co., Ltd
Condition:
Basic Science
Intervention:
Drug: 14C-RAY1225
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 15, 2026
Target Sample Size: 8
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07460284
Published by HT Digital Content...